Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Nam-In | - |
dc.contributor.author | Koo, Bon-Noon | - |
dc.contributor.author | Kim, Sung-Wan | - |
dc.contributor.author | Kim, Jong-Noon | - |
dc.contributor.author | Nam, Beomwoo | - |
dc.contributor.author | Lee, Bong-Ju | - |
dc.contributor.author | Lee, Sang-Hyuk | - |
dc.contributor.author | Lee, Seung Jae | - |
dc.contributor.author | Lee, Seung-Hwan | - |
dc.contributor.author | Jung, Myung Hun | - |
dc.contributor.author | Hahn, Sang Woo | - |
dc.contributor.author | Chung, Young-Chul | - |
dc.date.available | 2020-02-28T01:42:27Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 1738-1088 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8085 | - |
dc.description.abstract | Objective: We investigated the efficacy and tolerability of paliperidone extended-release (ER) tablets in patients with first-episode psychosis (n=75). Methods: This was an 8-week, open-label, multicenter trial. The primary outcome variable was scores on the Positive and Negative Syndrome Scale (PANSS); secondary measures included the Scale for the Assessment of Negative Symptoms (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of Functioning (GAF). To assess safety, we measured drug-related adverse events, weight, lipid-related variables, and prolactin and administered the Simpson-Angus Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU). Results: The administration of paliperidone ER resulted in significant improvement in the PANSS, SANS, CAI, and GAF scores (p<0.001) over time, This improvement was evident as early as 1 week, The most frequent adverse events were akathisia, somnolence, anxiety, and sedation, which were well tolerated. Modest increases in weight and lipid profiles were also noted. Prolactin levels were substantially increased at the endpoint in both male and female patients. Conclusion: These results indicate that paliperidone ER is effective and is characterized by good tolerability in the treatment of positive and negative symptoms and cognitive functioning in first-episode psychosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | - |
dc.relation.isPartOf | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | SCHIZOAFFECTIVE DISORDER | - |
dc.subject | ANTIPSYCHOTIC-DRUGS | - |
dc.subject | ACUTE SCHIZOPHRENIA | - |
dc.subject | TREATMENT RESPONSE | - |
dc.subject | TERM TREATMENT | - |
dc.subject | RATING-SCALE | - |
dc.subject | 1ST EPISODE | - |
dc.subject | POOLED DATA | - |
dc.subject | RISPERIDONE | - |
dc.title | Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000381780000005 | - |
dc.identifier.doi | 10.9758/cpn.2016.14.3.261 | - |
dc.identifier.bibliographicCitation | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, v.14, no.3, pp.261 - 269 | - |
dc.identifier.kciid | ART002137915 | - |
dc.identifier.scopusid | 2-s2.0-84988384057 | - |
dc.citation.endPage | 269 | - |
dc.citation.startPage | 261 | - |
dc.citation.title | CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | - |
dc.citation.volume | 14 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Kim, Jong-Noon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Paliperidone extended-release | - |
dc.subject.keywordAuthor | First-episode psychosis | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Tolerability | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | SCHIZOAFFECTIVE DISORDER | - |
dc.subject.keywordPlus | ANTIPSYCHOTIC-DRUGS | - |
dc.subject.keywordPlus | ACUTE SCHIZOPHRENIA | - |
dc.subject.keywordPlus | TREATMENT RESPONSE | - |
dc.subject.keywordPlus | TERM TREATMENT | - |
dc.subject.keywordPlus | RATING-SCALE | - |
dc.subject.keywordPlus | 1ST EPISODE | - |
dc.subject.keywordPlus | POOLED DATA | - |
dc.subject.keywordPlus | RISPERIDONE | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.